Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours Β· Estimated delivery Aug 18 - Aug 23
Indication for SOLIQUA 100/33 SOLIQUA 100/33 (insulin glargine and lixisenatide) is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Hydration and eating behaviors are frequently overlooked factors
Some individuals may experience changes within the first month
Combining stable GLP-1 therapy with sustainable lifestyle habits creates a dual mechanism that addresses both the biological and behavioral drivers of weight gain
Many people do not notice clear symptoms until a routine blood test shows prediabetes, high triglycerides, or another metabolic concern
Ask for a baseline eye exam before starting a GLP-1 drug, especially if you have diabetes
US$ 27.29
US$ 26.64
US$ 27.44
US$ 28.96
